Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

NeuroMetrix Inc

Change company Symbol lookup

Select an option...

NURO NeuroMetrix Inc

OTTW Ottawa Savings Bancorp Inc

HMC Honda Motor Co Ltd

PAVMZ PAVmed Series Z Equity Warrants Exp 30 Apr 2024 *W EXP 04/30/2024

FFBW Ffbw Inc

CIB Bancolombia SA

TARA Protara Therapeutics Inc

SLAMU Slam Corp

SY So-Young International Inc

BHR Braemar Hotels & Resorts Inc

Health Care : Health Care Equipment & Supplies | Small Cap Value

Company profile

NeuroMetrix, Inc. develops and commercializes health care products that utilize non-invasive neurostimulation. The Company is engaged in the designing, building and marketing of medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. It has two principal product categories, which includes point-of-care neuropathy diagnostic tests and wearable neurostimulation devices. Its products include DPNCheck, Quell and ADVANCE System. DPNCheck is a quantitative nerve conduction test that is used to evaluate peripheral neuropathies, such as Diabetic peripheral neuropathy (DPN). Quell a wearable device for symptomatic relief and management of chronic pain. ADVANCE System is a platform for the performance of nerve conduction studies. DPNCheck customers include managed care organizations, endocrinologists, podiatrists and primary care physicians. ADVANCE System customers include occupational health, primary care, internal medicine and many others.

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

5:17 pm ET April 20, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Regeneron Pharmaceuticals Inc. (REGN) inched 0.47% higher to $719.62 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.71% to 35,160.79 and the S&P 500 Index falling 0.06% to 4,459.45. The stock's rise snapped a two-day losing streak. Regeneron Pharmaceuticals Inc. closed $27.80 short of its 52-week high ($747.42), which the company achieved on April 8th.

The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Johnson & Johnson (JNJ) rose 0.44% to $183.89, Novartis AG ADR (NOVN.EB) fell 0.39% to $91.24, and Amgen Inc. (AMGN) rose 0.79% to $255.38. Trading volume (413,281) remained 268,082 below its 50-day average volume of 681,363.

Data source: Dow Jones Market Data, FactSet. Data compiled April 20, 2022.

-MarketWatch Automation

(END) Dow Jones Newswires

April 20, 2022 17:17 ET (21:17 GMT)